Clinical trial
Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)
NCT00214773 · BioMarin Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00214773 |
|---|---|
| Title | Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP) |
| Official title | MPS VI Clinical Surveillance Program (CSP) |
| Lead sponsor | BioMarin Pharmaceutical, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome) |
| Enrollment | 237 |
| Start date | Jul 1, 2005 |
| Primary completion | May 1, 2020 |
| Completion | May 1, 2020 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 5, 2021 |
| Countries | Australia, Austria, Belgium, France, Germany, Ireland, Italy, Lithuania, Netherlands, Portugal, Sweden, United Kingdom and 1 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: